DrugPatentWatch Database Preview
CABERGOLINE Drug Profile
or, see our see our flat-rate plans
When do Cabergoline patents expire, and what generic alternatives are available?
The generic ingredient in CABERGOLINE is cabergoline. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the cabergoline profile page.
Summary for CABERGOLINE
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 40 |
| Clinical Trials: | 43 |
| Patent Applications: | 2,469 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | CABERGOLINE at DailyMed |
Pharmacology for CABERGOLINE
| Ingredient-type | Ergolines |
| Drug Class | Ergot Derivative |
Synonyms for CABERGOLINE
| (6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide |
| (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide |
| (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide |
| (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide |
| (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide |
| 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea |
| 1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea |
| 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea |
| 1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea |
| 1-[3-(DIMETHYLAMINO)PROPYL]-3-ETHYL-1-[(2R,4R,7R)-6-(PROP-2-EN-1-YL)-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(15),9,12(16),13-TETRAENE-4-CARBONYL]UREA |
| 1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea |
| 1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0;{2,7}.0;{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea |
| 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate |
| 1-Ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'beta-carbonyl)urea |
| 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea |
| 409C907 |
| 6-allyl-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-ergoline-8beta-carboxamide |
| 81409-90-7 |
| 85329-89-1 (diphosphate) |
| AB01275484-01 |
| AC-26126 |
| AC1L1HO0 |
| AC1Q5OQ0 |
| AKOS015961587 |
| AN-36255 |
| BC207368 |
| BDBM50426497 |
| BIDD:GT0775 |
| BRD-K86882815-001-01-6 |
| BRN 6020775 |
| C08187 |
| C26H37N5O2 |
| Cabaser |
| Cabaser (TN) |
| Cabaseril |
| Cabergolina |
| Cabergolina [Spanish] |
| Cabergoline (JAN/USAN/INN) |
| Cabergoline [USAN:BAN:INN] |
| Cabergoline, >=98% (HPLC) |
| Cabergoline, European Pharmacopoeia (EP) Reference Standard |
| Cabergoline, United States Pharmacopeia (USP) Reference Standard |
| Cabergolinum |
| Cabergolinum [Latin] |
| Caberlin |
| CAS-81409-90-7 |
| CG-101 |
| CHEBI:3286 |
| CHEMBL1201087 |
| CTK8F8406 |
| D00987 |
| D04EGX |
| DB00248 |
| Dostinex |
| Dostinex (TN) |
| DR002797 |
| DSSTox_CID_2719 |
| DSSTox_GSID_22719 |
| DSSTox_RID_76698 |
| DTXSID6022719 |
| Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)- |
| Ergoline-8beta-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)- |
| FCE-21336 |
| FT-0081285 |
| FT-0650562 |
| Galastop |
| GTPL37 |
| HMS2090A09 |
| K450 |
| KORNTPPJEAJQIU-KJXAQDMKSA-N |
| LL60K9J05T |
| LS-64370 |
| MFCD00867887 |
| MolPort-003-845-557 |
| N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-allyl-ergoline-8beta-carboxamide |
| NCGC00167821-01 |
| NCGC00344544-01 |
| PL070592 |
| SC-19831 |
| SCHEMBL42292 |
| Sogilen |
| SR-05000001493 |
| SR-05000001493-2 |
| Tox21_112589 |
| Tox21_112589_1 |
| UNII-LL60K9J05T |
| ZINC3800008 |
US Patents and Regulatory Information for CABERGOLINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Labs Fl Inc | CABERGOLINE | cabergoline | TABLET;ORAL | 078035-001 | Apr 21, 2008 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Ivax Sub Teva Pharms | CABERGOLINE | cabergoline | TABLET;ORAL | 077750-001 | Mar 7, 2007 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Apotex Corp | CABERGOLINE | cabergoline | TABLET;ORAL | 201503-001 | Mar 8, 2013 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Impax Labs Inc | CABERGOLINE | cabergoline | TABLET;ORAL | 077843-001 | Jul 3, 2007 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
or, see our see our flat-rate plans
